Skip to content

Study · Case report or series · n = 1 · 2011

3 results

Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.

Carvalho NN, Voss LA, Almeida MO, Salgado CL, Bandeira F

The Journal of clinical endocrinology and metabolism13 Jul 2011Cited by 61 (Europe PMC)

PMID21752890 (opens in a new tab)DOI10.1210/jc.2011-0593 (opens in a new tab)PepBankPUB-21752890
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanCase report or seriesEfficacy outcome

    In a postmenopausal woman with an unhealed atypical femoral fracture, radiographic fracture closure occurred after 1 month of teriparatide.

    In plain wordsIn one postmenopausal woman, the unhealed femoral fracture closed after teriparatide treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRadiographic fracture closure
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/d · 1 monthAs given in this study (human).

    Source sentences

    Summary
    In case 3, after 1 month on teriparatide 20 μg/d, a radiographic closure of the fracture was achieved, and 3 months later serum osteocalcin and serum β-carboxyterminal telopeptide had increased by 300 and 22%, respectively.
    1 context sentence
    Summary · context
    We studied three postmenopausal women with a diagnosis of osteoporosis who suffered fractures of the subtrochanteric region and femoral diaphysis with no major trauma while on long-term use of bisphosphonates.
  2. 02HumanCase report or seriesEfficacy outcome

    In a postmenopausal woman receiving teriparatide, serum osteocalcin increased 300% after fracture closure.

    In plain wordsIn one postmenopausal woman receiving teriparatide, the bone formation marker increased from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum osteocalcin
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/dAs given in this study (human).

    Measurements

    Change in serum osteocalcin
    300%
    case 3, 3 months after fracture closure

    Source sentences

    Summary
    In case 3, after 1 month on teriparatide 20 μg/d, a radiographic closure of the fracture was achieved, and 3 months later serum osteocalcin and serum β-carboxyterminal telopeptide had increased by 300 and 22%, respectively.
    1 context sentence
    Summary · context
    We studied three postmenopausal women with a diagnosis of osteoporosis who suffered fractures of the subtrochanteric region and femoral diaphysis with no major trauma while on long-term use of bisphosphonates.
  3. 03HumanCase report or seriesEfficacy outcome

    In a postmenopausal woman receiving teriparatide, serum β-carboxyterminal telopeptide increased 22% after fracture closure.

    In plain wordsIn one postmenopausal woman receiving teriparatide, the bone resorption marker increased from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseSerum β-carboxyterminal telopeptide
    Study

    n = 1

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/dAs given in this study (human).

    Measurements

    Serum β-carboxyterminal telopeptide increase
    22%
    case 3, 3 months later

    Source sentences

    Summary
    In case 3, after 1 month on teriparatide 20 μg/d, a radiographic closure of the fracture was achieved, and 3 months later serum osteocalcin and serum β-carboxyterminal telopeptide had increased by 300 and 22%, respectively.
    1 context sentence
    Summary · context
    We studied three postmenopausal women with a diagnosis of osteoporosis who suffered fractures of the subtrochanteric region and femoral diaphysis with no major trauma while on long-term use of bisphosphonates.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.